August 2011

Subject: Non-interventional study on the off-label transplant use of plerixafor

Dear Colleague,

The EMA license for plerixafor requires Genzyme to perform the outcome monitoring of patients transplanted with plerixafor-mobilized cells, compared to equivalent patients transplanted without the use of plerixafor. The EMA has acceded the collaboration of Genzyme with EBMT to collect the required data by using the EBMT registry. For this purpose Genzyme and the EBMT have developed the CALM study (Collaboration to collect Autologous transplant outcomes in Lymphoma and Myeloma). As a post-marketing commitment to the EMA, Genzyme will additionally monitor the off-label transplant use of plerixafor using data in the EBMT registry.

The use of plerixafor in off-label settings will be collected from data entries over a 5-year period after the date of marketing authorization, namely data entered between 31 July 2009 and 31 July 2014.

It concerns patients treated with plerixafor, who meet one or more of the following conditions:

- Background disease other than lymphoma or MM
- Younger than 18 years of age
- Received transplant using ex-vivo plerixafor-mobilised cells
- Received treatment with plerixafor alone
- Contraindication for G-CSF
- Transplants using plerixafor-mobilised cells from allogeneic donor
- Received transplant using plerixafor-mobilised BM cells
- Routes of administration other than subcutaneous
- Patients whose cells do not mobilise poorly
- Other

In case this invitation does not apply to your department, could you please forward these documents to the appropriate department? We hope that you will help us and make the study generally known in your centre.

European Group for Blood and Marrow Transplantation

EBMT Data Office Leiden
Department of Medical Statistics and Bioinformatics
Postal zone S-05-P
Leiden University Medical Center
P.O. Box 9600
2300 RC Leiden
The Netherlands

www.ebmt.org
Data request

Centres should include all consecutive eligible patients. The patient registration form collects only the off-label transplant use indication and patient identification items. EBMT expects your data forms to be registered at day 100 after transplant as usual.

For the patients transplanted and registered prospectively with the EBMT, in general no ethical approval is necessary. However, regulations on approval may differ per centre. Please contact you EC in case of any doubts. It is sufficient to collect the general patient consent forms for data submission to the EBMT registry.

The invitation letter, study protocol, summary of the protocol, information for the Ethics Committee, patient registration form/MED C (without the flowchart) and leaflet can be downloaded from the website:


To participate in this EBMT study, please complete the patient registration form(s) and return these to the EBMT Data Office in Leiden, The Netherlands, via fax at +49 711 4900 8723, or e-mail at plerolebmt@lumc.nl.

Thank you again for your cooperation.

Sincerely,

Annelies Kleijne
Study Coordinator

Curly Morris
Myeloma subcette

Anna Sureda
Lymphoma WP

Anja van Biezen
Head Data Office

Theo de Witte
Chair CLWP

Peter Dreger
Chair LWP

EBMT Data Office Leiden
Telephone: +31 71 526 4746
Fax (to e-mail system) 1: +49 711 4900 8723
Fax (to e-mail system) 2: +49 180 500 290 623
E-mail: plerolebmt@lumc.nl